Interdisciplinary problem of post-transplant diabetes mellitus: literature review
https://doi.org/10.47093/2218-7332.2021.12.1.60-73
摘要
The number of transplantation and transplant survival rates increase steadily. Patients after solid organ transplantation re-ceive lifelong immunosuppressive therapy which may have adverse effects on carbohydrate and lipid metabolism. The most diabetogenic drugs are calcineurin inhibitors and corticosteroids. Posttransplant diabetes mellitus (PTDM) is hyperglycemia that meets American Diabetes Association and World Health Organization diabetes criteria for nontransplant patients and that was newly diagnosed after transplantation. PTDM may worsen both short-term and long-term transplantation outcomes so that the problem of timely diagnosis, proper treatment and prevention is critical. In early post-transplant period, transient hyperglycemia is found in the vast majority of patients; therefore, PTDM screening is carried out at least one month after transplantation. The gold standard test for PTDM diagnosis is oral glucose tolerance test. In the same time diagnostic value of hemoglobin A1C is limited. Lifestyle therapy and antidiabetic drugs are considered as possible preventive measures. Stress induced hyperglycemia management in solid organ recipients is the same with other surgical patients. Which organ was transplanted, patient characteristics and possible drug interactions with immunosuppressive therapy should be taken into account while managing PTDM. Blood pressure and lipid profile should be under control for comprehensive cardiovascu-lar risk reduction. It remains unclear which PTDM treatment and prevention strategy is the best and for better understanding interdisciplinary approach is needed.
关于作者
A. Balashova
Sechenov First Moscow State Medical University (Sechenov University)
俄罗斯联邦
俄罗斯联邦
V. Mustafina
Sechenov First Moscow State Medical University (Sechenov University)
俄罗斯联邦
俄罗斯联邦
I. Glinkina
Sechenov First Moscow State Medical University (Sechenov University)
俄罗斯联邦
俄罗斯联邦
参考
1. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2019 году. XII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2020; 22(2): 8–34. https://doi.org/10.15825/1995-1191-2020-2-8-34
2. Wang J.H., Skeans M.A., Israni A.K. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016; 23(5): 281–286. https://doi.org/10.1053/j.ackd.2016.07.001 PMID: 27742381
3. Stehlik J., Edwards L. B., Kucheryavaya A. Y., et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. J Heart Lung Transplant. 2012 Oct; 31(10): 1052–1064. https://doi.org/10.1016/j.healun.2012.08.002 PMID: 22975095
4. Готье С.В., Шевченко А.О., Попцов В.Н. Пациент с трансплантированным сердцем. Руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. М. – Тверь: ООО «Издательство «Триада», 2014. 144 с.
5. Shivaswamy V., Boerner B., Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016 Feb; 37(1): 37–61. https://doi.org/10.1210/er.2015-1084 PMID: 26650437
6. Sharif A., Hecking M., de Vries A.P., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14(9): 1992–2000. https://doi.org/10.1111/ajt.12850 PMID: 25307034
7. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF Consultation. Geneva, Switzerland: WHO; 2006. 50 p.
8. Park S.C., Yoon Y.D., Jung H.Y., et al. Effect of transient posttransplantation hyperglycemia on the development of diabetes mellitus and transplantation outcomes in kidney transplant recipients. Transplant Proc. 2015 Apr; 47(3): 666–671. https://doi.org/10.1016/j.transproceed.2014.11.05.3 PMID: 25891707
9. Boerner B., Shivaswamy V., Goldner W., Larsen J. Management of the hospitalized transplant patient. Curr Diab Rep. 2015 Apr; 15(4): 19. https://doi.org/10.1007/s11892-015-0585-6 PMID: 25721247
10. Valderhaug T.G., Jenssen T., Hartmann A., et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009; 88(3): 429–434. https://doi.org/10.1097/TP.0b013e3181af1f53 PMID: 19667949
11. Jenssen T., Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019; 15(3): 172–188. https://doi.org/10.1038/s41574-018-0137-7 PMID: 30622369
12. Новикова М.С., Аллазова С.С., Котенко О.Н., Шилов Е.М. Посттрансплантационный сахарный диабет у пациентов с аллотрансплантацией почки. Клиническая нефрология. 2018; 4: 20–24. https://dx.doi.org/10.18565/nephrology.2018.4.20-24
13. Прокопенко Е.И., Ватазин А.В., Щербакова Е.О. Посттрансплантационный сахарный диабет у реципиентов ренального трансплантата: опыт одного центра. Нефрология. 2017; 21(6): 20–28. https://doi.org/10.24884/1561-6274-2017-21-6-20-28
14. Мовчан Е.А., Ким Ю.Ю., Рябцева Е.П., Галкина Е.В. Посттрансплантационный сахарный диабет. Journal of Siberian Medical Sciences. 2018; 4: 26–33. https://doi.org/10.31549/2542-1174-2018-4-26-33
15. Lane J.T., Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab. 2011; 96(11): 3289–3297. https://doi.org/10.1210/jc.2011-0657 PMID: 22058376
16. Sharif A., Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2010; 6(7): 415–423. https://doi.org/10.1038/nrneph.2010.66 PMID: 20498675
17. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11): 866–875. https://doi.org/10.1016/S2213-8587(15)00291-0 PMID: 26377054
18. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова 9-й выпуск. Сахарный диабет. 2019; 22 (1S1): 1–144. https://doi.org/10.14341/DM221S1
19. Hecking M., Haidinger M., Döller D., et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012; 23(4): 739–749. https://doi.org/10.1681/ASN.2011080835 PMID: 22343119
20. Allison T.L. Immunosuppressive Therapy in Transplantation. Nurs Clin North Am. 2016 Mar; 51(1): 107–120. https://doi.org/10.1016/j.cnur.2015.10.008 PMID: 26897428
21. Bloom R.D., Rao V., Weng F., et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002; 13(5): 1374–1380. https://doi.org/10.1097/01.asn.0000012382.97168.e0/ PMID: 11961026
22. Øzbay L.A., Møller N., Juhl C., et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol. 2012; 73(4): 536–545. https://doi.org/10.1111/j.13652125.2011.04118.x PMID: 21988494
23. Shivaswamy V., Bennett R.G., Clure C.C., et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats. Transl Res. 2014; 163(3): 221–231. https://doi.org/10.1016/j.trsl.2013.12.002 PMID: 24361102
24. Tanimura J., Nakagawa H., Tanaka T., et al. The clinical course and potential underlying mechanisms of everolimusinduced hyperglycemia. Endocr J. 2019 Jul 28; 66(7): 615–620. https://doi.org/10.1507/endocrj.EJ18-0542 PMID: 30982794
25. Sommerer C., Witzke O., Lehner F., et al. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol. 2018 Sep; 19(1): 237. https://doi.org/10.1186/s12882-018-1031-1 PMID: 30231851
26. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009; 9(3): S1–155. https://doi.org/10.1111/j.1600-6143.2009.02834.x PMID: 19845597
27. Лазарева К.Е., Ржевская О.Н., Загородникова Н.В. Причины развития и методы коррекции посттрансплантационного сахарного диабета. Трансплантология. 2017; 9(4): 335–349. https://doi.org/10.23873/2074-0506-2017-9-4-335-349
28. Boudreaux J.P., McHugh L., Canafax D.M., et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987; 44(3): 376–381. https://doi.org/10.1097/00007890-198709000-00010 PMID: 3307061
29. Hjelmesaeth J., Hartmann A., Leivestad T., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006; 69(3): 588–595. https://doi.org/10.1038/sj.ki.5000116 PMID: 16395250
30. Hermayer K.L., Egidi M.F., Finch N.J., et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab. 2012; 97(12): 4399–4406. https://doi.org/10.1210/jc.2012-1979 PMID: 23074234
31. Morbitzer K.A., Taber D.J., Pilch N.A., et al. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clin Transplant. 2014; 28: 862–868. https://doi.org/10.1111/ctr.12391 PMID: 24893750
32. Garcia C., Wallia A., Gupta S., et al. Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clin Transplant. 2013; 27(3): 444–454. https://doi.org/10.1111/ctr.12118 PMID: 23574363
33. Vanhove T., Remijsen Q., Kuypers D., Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev (Orlando). 2017; 31(2): 69–77. https://doi.org/10.1016/j.trre.2016.09.001 PMID: 27665059
34. Stephen J., Anderson-Haag T.L., Gustafson S., et al. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol. 2014; 40(6): 546–553. https://doi.org/10.1159/000370034 PMID: 25613554
35. Vest L.S., Koraishy F.M., Zhang Z., et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant. 2018; 32(8): e13302. https://doi.org/10.1111/ctr.13302 PMID: 29851159
36. Haidinger M., Werzowa J., Hecking M., et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation – a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014; 14(1): 115–123. https://doi.org/10.1111/ajt.12518 PMID: 24279801
37. Türk T., Pietruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006; 6(4): 842–846. https://doi.org/10.1111/j.1600-6143.2006.01250.x PMID: 16539642
38. Haidinger M., Antlanger M., Kopecky C., et al. Posttransplantation diabetes mellitus: evaluation of treatment strategies. Clin Transplant. 2015; 29(5): 415–424. https://doi.org/10.1111/ctr.12541 PMID: 25777150
39. Boerner B.P., Miles C.D., Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014; 2014: 617638. https://doi.org/10.1155/2014/617638 PMID: 24817885
40. Lane J.T., Odegaard D.E., Haire C.E., et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011; 92(10): e56–57. https://doi.org/10.1097/TP.0b013e3182347ea4 PMID: 22067216
41. Strøm Halden T.A., Åsberg A., Vik K., et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant. 2014; 29(4): 926–933. https://doi.org/10.1093/ndt/gft536 PMID: 24452849
42. Gueler I., Mueller S., Helmschrott M., et al. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des Devel Ther. 2013; 7: 297–303. https://doi.org/10.2147/DDDT.S43092 PMID: 23630415
43. Halden T.A.S., Egeland E.J., Åsberg A., et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes. Diabetes Care. 2016; 39(4): 617–624. https://doi.org/10.2337/dc15-2383 PMID: 26908914
44. Pinelli N.R., Patel A., Salinitri F.D. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013; 36(10): e171–172. https://doi.org/10.2337/dc13-1066 PMID: 24065848
45. Vallon V., Gerasimova M., Rose M.A., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014; 306(2): F194–204. https://doi.org/10.1152/ajprenal.00520.2013 PMID: 24226524
46. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128. https://doi.org/10.1056/NEJMoa1504720 PMID: 26378978
47. Mahling M., Schork A., Nadalin S., et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res. 2019; 44(5): 984–992. https://doi.org/10.1159/000501854 PMID: 31437852
48. Rajasekeran H., Kim S.J., Cardella C.J., et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series. Diabetes Care. 2017; 40(7): e75–76. https://doi.org/10.2337/dc17-0237 PMID: 28416475
49. Cehic M., Greenfield J., Hayward Ch., et al. Impact of empagliflozin for the treatment of diabetes mellitus after heart transplantation. Transplantation. 2018; 102(7): S88. https://doi.org/10.1097/01.tp.0000542675.44943.1c
补充文件
评论
浏览:
3958
Email this article 